Blue Trust Inc. Has $39,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Blue Trust Inc. grew its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 174.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,008 shares of the biopharmaceutical company’s stock after purchasing an additional 641 shares during the period. Blue Trust Inc.’s holdings in Xenon Pharmaceuticals were worth $39,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Driehaus Capital Management LLC lifted its holdings in shares of Xenon Pharmaceuticals by 2.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock worth $172,315,000 after acquiring an additional 97,732 shares during the period. Capital International Investors lifted its holdings in Xenon Pharmaceuticals by 0.8% during the 1st quarter. Capital International Investors now owns 2,475,859 shares of the biopharmaceutical company’s stock valued at $106,586,000 after purchasing an additional 20,176 shares during the last quarter. Affinity Asset Advisors LLC lifted its holdings in Xenon Pharmaceuticals by 18.7% during the 2nd quarter. Affinity Asset Advisors LLC now owns 994,227 shares of the biopharmaceutical company’s stock valued at $38,765,000 after purchasing an additional 156,840 shares during the last quarter. Lord Abbett & CO. LLC lifted its holdings in Xenon Pharmaceuticals by 24.7% during the 1st quarter. Lord Abbett & CO. LLC now owns 895,196 shares of the biopharmaceutical company’s stock valued at $38,539,000 after purchasing an additional 177,224 shares during the last quarter. Finally, Samlyn Capital LLC lifted its holdings in Xenon Pharmaceuticals by 61.5% during the 2nd quarter. Samlyn Capital LLC now owns 639,685 shares of the biopharmaceutical company’s stock valued at $24,941,000 after purchasing an additional 243,489 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $41.69 on Friday. Xenon Pharmaceuticals Inc. has a one year low of $27.99 and a one year high of $50.99. The company has a market cap of $3.16 billion, a P/E ratio of -15.22 and a beta of 1.25. The firm’s fifty day moving average price is $40.61 and its two-hundred day moving average price is $40.17.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.05). During the same quarter in the previous year, the business posted ($0.72) EPS. As a group, equities research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on XENE shares. Needham & Company LLC lowered their price objective on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Raymond James restated an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. Finally, Wedbush lowered their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $57.45.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.